Atossa updates corporate presentation on (Z)-Endoxifen programs
Atossa Therapeutics made an updated corporate presentation available highlighting (Z)-Endoxifen clinical progress, regulatory designations and $26.1 million cash.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.